Cargando…
Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state
Pompe disease is an autosomal recessive, lysosomal glycogen storage disease caused by acid α-glucosidase deficiency. Infantile-onset Pompe disease (IOPD) is the most severe form and is characterized by cardiomyopathy, respiratory distress, hepatomegaly, and skeletal muscle weakness. Untreated, IOPD...
Autores principales: | Matsuoka, Takashi, Miwa, Yoshiyuki, Tajika, Makiko, Sawada, Madoka, Fujimaki, Koichiro, Soga, Takashi, Tomita, Hideshi, Uemura, Shigeru, Nishino, Ichizo, Fukuda, Tokiko, Sugie, Hideo, Kosuga, Motomichi, Okuyama, Torayuki, Umeda, Yoh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121151/ https://www.ncbi.nlm.nih.gov/pubmed/27896132 http://dx.doi.org/10.1016/j.ymgmr.2016.11.001 |
Ejemplares similares
-
Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up
por: Furujo, Mahoko, et al.
Publicado: (2017) -
A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan
por: Fukuhara, Yasuyuki, et al.
Publicado: (2017) -
Letter to the Editors: Concerning “Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state” by Takashi et al. and Letter to the Editors by Ortolano et al.
por: Schänzer, Anne, et al.
Publicado: (2017) -
Normal early development in siblings with novel compound heterozygous variants in ASPM
por: Moriwaki, Taro, et al.
Publicado: (2020) -
Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
por: Seo, Joo-Hyun, et al.
Publicado: (2021)